<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002453</url>
  </required_header>
  <id_info>
    <org_study_id>283C</org_study_id>
    <secondary_id>GS-99-908</secondary_id>
    <nct_id>NCT00002453</nct_id>
  </id_info>
  <brief_title>A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection</brief_title>
  <official_title>An Open-Label, Multicenter, Compassionate Access Study of the Safety of Tenofovir Disoproxil Fumarate Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      This study allows patients who need a new anti-HIV treatment to take tenofovir disoproxil&#xD;
      fumarate (tenofovir DF), an experimental drug. This study also looks at any side effects the&#xD;
      drug causes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-1-infected patients who are currently receiving stable antiretroviral therapy add&#xD;
      tenofovir DF to their regimen. Study participation lasts for approximately 48 weeks.&#xD;
      Interested patients should contact their physicians.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>300</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        You may be eligible for this study if you:&#xD;
&#xD;
          -  Are HIV-positive.&#xD;
&#xD;
          -  Have a viral load greater than or equal to 10,000 copies/ml.&#xD;
&#xD;
          -  Have a CD4 count less than or equal to 50 cells/mm3, or have a CD4 count greater than&#xD;
             50 and no more than 200 cells/mm3 with an opportunistic (AIDS-related) infection&#xD;
             within 90 days of study entry. (Patients with a CD4 count above 200 cells/mm3 may be&#xD;
             considered depending on drug supply.)&#xD;
&#xD;
          -  Are at least 18 years old.&#xD;
&#xD;
          -  Agree to use barrier methods of birth control (such as condoms) while on the study and&#xD;
             for 30 days afterward.&#xD;
&#xD;
          -  Have a life expectancy of at least one year.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        You will not be eligible for this study if you:&#xD;
&#xD;
          -  Have a history of a serious kidney or bone disease.&#xD;
&#xD;
          -  Have severe nausea, vomiting, or trouble taking medications by mouth.&#xD;
&#xD;
          -  Are pregnant or breast-feeding.&#xD;
&#xD;
          -  Abuse alcohol or other substances that your doctor thinks would interfere with taking&#xD;
             this medicine.&#xD;
&#xD;
          -  Are taking any medicines that interfere with kidney functions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tenofovir Coordinating Center</name>
      <address>
        <city>Foster City</city>
        <state>California</state>
        <zip>94404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2000</verification_date>
  <study_first_submitted>January 24, 2000</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>HIV-1</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Disease Progression</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

